PAR-23-043: Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R61/R33 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on March 9, 2023.
From the official notice on Grants.gov, last changed December 7, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsRequired
- Funded byNHLBI
- Median yearly award$335,808
- Typical project length3 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under PAR-23-043 were run by National Heart Lung and Blood Institute (NHLBI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-23-043 in the NIH Guide.
Key dates
| Posted | December 7, 2022 |
|---|---|
| Deadline | March 9, 2023 |
| Archived by Grants.gov | April 14, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 5 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (AI/AN) Tribal Nation populations in the United States. This Funding Opportunity Announcement (FOA) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. Specifically, this FOA invites applications that propose implementation research targeted to reducing the risks of NCDs in the context of cities in LMICs and/or among AI/AN Tribal Nation populations in cities in the United States, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. In the context of this FOA, "cities" include urban centers, informal settlements and slums, and periurban areas. This FOA uses the bi-phasic, milestone driven R61/R33 grant mechanism. Awards made under this FOA will initially support a two-year milestone-driven initiation (R61) phase, with possible transition to an implementation (R33) phase of up to 3 additional years. Only projects that meet the scientific milestones and award requirements of the R61 phase may transition to the R33 phase. Applications submitted in response to this FOA must address both the R61 and R33 phases.
Funded under PAR-23-043 so far
NIH funded 6 projects under PAR-23-043 in fiscal 2024 to 2026, at 3 institutions. The median yearly award was $335,808.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Coaching and Navigation by CHWs through Telehealth for High-risk Hypertension | Weill Medical Coll of Cornell Univ | 2026 | $318,670 |
| Conquering Hypertension in Urban Vietnam | Univ of Massachusetts Med Sch Worcester | 2026 | $252,560 |
| Community Vital Signs (CVS): An integrated community-based approach to identify undiagnosed hypertension in Nigeria | Oregon Health & Science University | 2026 | $348,774 |
| Coaching and Navigation by CHWs through Telehealth for High-risk Hypertension | Weill Medical Coll of Cornell Univ | 2024 | $657,012 |
| Community Vital Signs (CVS): An integrated community-based approach to identify undiagnosed hypertension in Nigeria | Oregon Health & Science University | 2024 | $633,755 |
| Conquering Hypertension in Urban Vietnam | Univ of Massachusetts Med Sch Worcester | 2024 | $724,064 |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Mental Health Research Grants grants before
From fiscal 2021 to 2025, Mental Health Research Grants (93.242) awarded $8.8 billion across 6,785 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 185 | $371 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 200 | $297 million |
| University of California, Los Angeles | California | 176 | $234 million |
| Icahn School of Medicine at Mount Sinai | New York | 144 | $212 million |
| The Washington University | Missouri | 149 | $211 million |
Who has won International Research and Research Training grants before
From fiscal 2021 to 2025, International Research and Research Training (93.989) awarded $329 million across 802 grant awards, an average of $409,951 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 19 | $13.2 million |
| Makerere University College of Health Sciences | 28 | $10.2 million | |
| The Johns Hopkins University | Maryland | 20 | $9.5 million |
| University of North Carolina at Chapel Hill | North Carolina | 22 | $9.3 million |
| University of Maryland, Baltimore | Maryland | 14 | $8.7 million |
Other programs behind this notice
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-23-043 still open?
No. It closed on March 9, 2023.
Who can apply for Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R61/R33 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R61/R33 Clinical Trial Required)?
Closed March 9, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-23-043?
NIH RePORTER lists 6 projects funded under PAR-23-043 in fiscal 2024 to 2026, at 3 institutions. The most were at Weill Medical Coll of Cornell Univ, Univ of Massachusetts Med Sch Worcester, Oregon Health & Science University.
Who has won Mental Health Research Grants grants before?
The largest recipients over five fiscal years were Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, University of California, Los Angeles. The program made 6,785 awards worth $8.8 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)